Thank you for Subscribing to Med Tech Business Review Weekly Brief
Medtech Business Review | Tuesday, September 01, 2026
Connected medical products are changing what manufacturers expect from compliance and certification testing labs. A device may now combine electronics, software, patient-contacting materials and data connectivity. Each layer introduces safety questions that cannot be reviewed in isolation.
This shift has made multidisciplinary testing more important. A product team may need evidence for electrical safety, biological evaluation, software behavior and cybersecurity controls. These areas are connected because a change in one part of the product can affect the others. A material change may alter biocompatibility evidence. A software update may affect risk files and the validation scope.
Electrical and electronic medical products often use standards such as IEC 60601-1, which offers wide requirements for basic safety and essential performance. The IEC states that IEC 60601-1 is generally applicable to medical electrical equipment and may be supplemented by collateral or particular standards, depending on the type of device.
Another crucial topic is biological safety. The requirements and general guidelines for assessing biological safety in a risk management procedure are outlined in ISO 10993-1:2025. This approach is important since the type of evidence required can vary depending on patient exposure, duration of use, material interaction, and intended clinical environment.
These streams of evidence must now be coordinated by manufacturers with the assistance of testing labs. Running independent tests is not the only difficulty. It involves ensuring that the outcomes support a logical risk rationale. The manufacturer's understanding of the device as a system rather than a collection of disparate parts is what regulators and certifying bodies want to see.
Additional pressure is added by software-driven products. As cybersecurity standards continue to advance, updates may be made after launch. The definition of product conformity is altered as a result. Processes that can accommodate post-market modifications without eroding safety evidence or producing ambiguous documentation trails are essential for manufacturers.
Technical breadth is necessary for labs that cater to this sector. In addition to having a practical understanding of device creation, they must comprehend test procedures and standards terminology. Products that undergo design revisions might not be compatible with a strict testing protocol. Manufacturers can plan evidence around potential modifications with a more practical approach.
The effect on the business is significant. Delays in one testing domain may affect the entire submission or certification schedule. If manufacturers undervalue this interaction, they can subsequently discover that the evidence is insufficient or erroneous. Products with various uses are especially susceptible to this problem.
Labs that can collaborate across disciplines while maintaining a coherent compliance narrative will be preferred for the next stage of medical product testing. Separate certificates are not enough for connected devices. They need proof that the complete product can function safely in actual clinical settings.